Junshi Biosciences announced positive results for their product, a monoclonal antibody for treating plaque psoriasis. The Phase 3 clinical study showed significant improvements in patients with moderate to severe psoriasis, with plans to submit for regulatory approval soon. Psoriasis affects millions globally, leading to physical and mental health issues. The study, led by Professor Jianzhong ZHANG, met all primary and secondary endpoints, demonstrating the product’s efficacy and safety. Results will be presented at future conferences. Junshi Biosciences aims to provide innovative therapies for patients, with a focus on autoimmune diseases like psoriasis and ankylosing spondylitis.

Read more at GlobeNewswire: Junshi Biosciences Announces the Phase 3 Study of JS005